Drug Profile


Alternative Names: APO866; FK 866; NMPRTs

Latest Information Update: 31 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma GmbH
  • Developer TopoTarget Switzerland
  • Class Acrylamides; Antineoplastics; Piperidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Nicotinamide phosphoribosyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Cutaneous T cell lymphoma; Malignant melanoma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 27 Jul 2015 No recent reports of development identified - Phase-II for Cutaneous T-cell lymphoma in the European Union and Switzerland (IV)
  • 02 Jun 2015 TopoTarget terminates a phase-II trial in Cutaneous T-cell lymphoma in European Union and Switzerland due to lack of efficacy (NCT00431912)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top